Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.

Authors

Douglas W. Blayney

Stanford University, Stanford, CA

Douglas W. Blayney , Yuankai Shi , Hryhorii Adamchuk , David Feng , Qingyuan Zhang , Lihua Du , Lan Huang , Ramon Mohanlal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).

First Author: Yuankai Shi

insert_chart_outlined

Poster

2021 ASCO Quality Care Symposium

bookmark_border

Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).

First Author: Jaime Shaw

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (φ) 2 results from a head-to-head comparison with Pegfilgrastim (Peg).

First Author: Douglas W. Blayney

insert_chart_outlined

Poster

2019 Supportive Care in Oncology Symposium

bookmark_border

Eflapegrastim, a novel, long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.

First Author: Lee S. Schwartzberg